Charles River Laboratories International, Inc. (CRL): Price and Financial Metrics
Charles River Laboratories International, Inc. (CRL)
Today's Latest Price: $227.70 USD
Updated Oct 30 7:00pm
Add CRL to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
CRL Stock Summary
- CRL has a market capitalization of $11,326,395,940 -- more than approximately 86.01% of US stocks.
- Price to trailing twelve month operating cash flow for CRL is currently 19.23, higher than 78.49% of US stocks with positive operating cash flow.
- In terms of twelve month growth in earnings before interest and taxes, Charles River Laboratories International Inc is reporting a growth rate of 41.09%; that's higher than 79.95% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to Charles River Laboratories International Inc are CLGX, RXN, EV, G, and TTEK.
- Visit CRL's SEC page to see the company's official filings. To visit the company's web site, go to www.criver.com.
CRL Stock Price Chart Interactive Chart >
CRL Price/Volume Stats
| Current price | $227.70 | 52-week high | $250.29 |
| Prev. close | $228.94 | 52-week low | $95.58 |
| Day low | $220.87 | Volume | 488,724 |
| Day high | $229.74 | Avg. volume | 395,491 |
| 50-day MA | $224.59 | Dividend yield | N/A |
| 200-day MA | $180.37 | Market Cap | 11.31B |
Charles River Laboratories International, Inc. (CRL) Company Bio
Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.
CRL Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $227.70 | $143.28 | -35% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Charles River Laboratories International Inc. To summarize, we found that Charles River Laboratories International Inc ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for CRL, they are:
- Interest coverage, a measure of earnings relative to interest payments, is 5.92; that's higher than 62.98% of US stocks in the Healthcare sector that have positive free cash flow.
- Charles River Laboratories International Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 24.34% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -37% |
| 1% | -36% |
| 2% | -35% |
| 3% | -35% |
| 4% | -34% |
| 5% | -34% |
Want more companies with a valuation profile/forecast similar to that of Charles River Laboratories International Inc? See GSK, CMD, MD, PRGO, and ENDP.
Loading social stream, please wait...